Panobinostat Effective in Patients With Myeloma who Received ≥2 Prior Therapies

Share this content:
Clear progression-free survival benefit for panobinostat plus bortezomib and dexamethasone among patients with multiple myeloma.
Clear progression-free survival benefit for panobinostat plus bortezomib and dexamethasone among patients with multiple myeloma.

There is a clear progression-free survival benefit for panobinostat plus bortezomib and dexamethasone among patients with multiple myeloma who received 2 or more prior regimens including bortezomib and an immunomodulatory agent, a new study published online ahead of print in the journal Blood has shown.1

Panobinostat, a potent pan-deacetylase inhibitor that affects the growth and survival of multiple myeloma cells through alteration of epigenetic mechanisms and protein metabolism, led to a significant improvement in progression-free survival when used in combination with bortezomib and dexamethasone in patients with relapsed and refractory multiple myeloma in the PANORAMA 1 trial. In a subgroup analysis, researchers sought to evaluate outcomes of patients in that phase 3 trial based on prior treatment.

Of those included in the study, 485 had received a prior immunomodulatory agent, 193 had received prior bortezomib and an immunomodulatory agent, 147 had received 2 or more regimens including bortezomib and an immunomodulatory agent.

Results showed that median progression-free survival for patients who received 2 or more therapies was 12.5 months in the panobinostat and 4.7 months in the placebo group (HR, 0.47; 95% CI, 0.31 - 0.72).

RELATED: FDA Approves Ixazomib for Relapsed, Refractory Multiple Myeloma

In those who received a prior immunomodulatory agent, median progression-free survival was 12.3 months with panobinostat vs 7.4 months with placebo (HR, 0.54; 95% CI, 0.43 - 0.68), and 10.6 months vs 5.8 months, respectively, in those who had received bortezomib and an immunomodulatory agent (HR, 0.52; 95% CI, 0.36 - 0.76).

In regard to safety, the most common grade 3 or 4 adverse events in the panobinostat group were thrombocytopenia, lymphopenia, neutropenia, diarrhea, and asthenia/fatigue. Of note, on-treatment deaths among those who received a prior immunomodulatory agent and bortezomib, regardless of prior regimen number, were similar between the 2 treatment groups.

Reference

  1. Richardson PG, Hungria VTM, Yoon S-S, et al. Panobinostat plus bortezomib and dexamethasone in relapsed/relapsed and refractory myeloma: outcomes by prior treatment [published online ahead of print December 2, 2015]. Blood. doi: 10.1182/blood-2015-09-665018.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs